IL-8

BerGenBio Announces New Preclinical Data Indicating Broadened Potential for Bemcentinib to Treat Severe Respiratory Infections

Retrieved on: 
Wednesday, February 7, 2024
IL-8, COVID-19, Inflammation, Cytokine, Urinary tract infection, Downregulation and upregulation, MD, Therapy, Patient, University, Lung, Rhinovirus, Acute respiratory distress syndrome, Protein, RSV, Infection, Neutrophil, Blood, AXL, IL-6, Viral

The data presented by Dr. Spalluto showed bemcentinib had activity in human in vitro models of infection caused by Respiratory Syncytial Virus (RSV), influenza and rhinovirus.

Key Points: 
  • The data presented by Dr. Spalluto showed bemcentinib had activity in human in vitro models of infection caused by Respiratory Syncytial Virus (RSV), influenza and rhinovirus.
  • In these models, bemcentinib downregulated IL-6 and IL-8, two important inflammatory cytokines associated with the severity of hospitalized respiratory infections.
  • Clinically, patients with viral respiratory infections can develop acute respiratory distress syndrome (ARDS), a life-threatening condition.
  • We look forward to conducting additional preclinical evaluation of bemcentinib's activity in severe respiratory infections to further bolster our understanding in this important area."

BerGenBio Announces New Preclinical Data Indicating Broadened Potential for Bemcentinib to Treat Severe Respiratory Infections

Retrieved on: 
Wednesday, February 7, 2024
IL-8, COVID-19, Inflammation, Cytokine, Urinary tract infection, Downregulation and upregulation, MD, Therapy, Patient, University, Lung, Rhinovirus, Acute respiratory distress syndrome, Protein, RSV, Infection, Neutrophil, Blood, AXL, IL-6, Viral

The data presented by Dr. Spalluto showed bemcentinib had activity in human in vitro models of infection caused by Respiratory Syncytial Virus (RSV), influenza and rhinovirus.

Key Points: 
  • The data presented by Dr. Spalluto showed bemcentinib had activity in human in vitro models of infection caused by Respiratory Syncytial Virus (RSV), influenza and rhinovirus.
  • In these models, bemcentinib downregulated IL-6 and IL-8, two important inflammatory cytokines associated with the severity of hospitalized respiratory infections.
  • Clinically, patients with viral respiratory infections can develop acute respiratory distress syndrome (ARDS), a life-threatening condition.
  • We look forward to conducting additional preclinical evaluation of bemcentinib's activity in severe respiratory infections to further bolster our understanding in this important area."

NeuBase Presents Non-Human Primate Data Illustrating Stealth Editors™ are Non-Immunogenic, Opening the Door to Redosing

Retrieved on: 
Thursday, June 29, 2023
MSD, DNA, MC3, APS, Serum, Gene editing, Mutation, IL-6, IL10, PNA, Dietrich Stephan, Development, IL-8, Blood, Immune system, Nucleic acid, Frameshift mutation, NHP, Cytokine, Research, LNP, Therapy, Death, Oligonucleotide, Pharmacology, Genome, Vaccine, Palladium, Stealth

For these reasons, we are on a mission to develop the next generation of editors that are non-immunogenic,” continued Dr. Stephan.

Key Points: 
  • For these reasons, we are on a mission to develop the next generation of editors that are non-immunogenic,” continued Dr. Stephan.
  • The conclusion from these data is that Stealth Editors do not elicit innate nor acquired immune responses in the encapsulated format in which they would be administered systemically.
  • The Company believes this is likely to be an important differentiator of its technology when transitioned to in vivo gene editing.
  • Ex vivo Editing with Stealth Editors - The Company investigated the capabilities of a new editing system to effectively edit human cells ex vivo.

Reviva Pharmaceuticals Announces Intent to File an IND for Brilaroxazine in Psoriasis After Promising Preclinical Data

Retrieved on: 
Thursday, May 11, 2023
Malignancy, Central nervous system, Depression, Schizophrenia, ISID, Pathology, Psoriasis, Quality of life, IL-6, Mental, Imiquimod, CNS, RP5063, Patent, DSM-IV codes, Patient, IL-8, Comorbidity, Risk, BALB/c, Toxic encephalopathy, Serotonin, IND, Pharmaceutical industry, Dopamine, Brilaroxazine

CUPERTINO, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), respiratory and metabolic diseases, has presented promising preclinical data on the potential of novel serotonin-dopamine stabilizer brilaroxazine for the treatment of psoriasis at the First International Societies for Investigative Dermatology (ISID) Meeting in Tokyo, Japan, May 10-13, 2023. The ISID poster is available at revivapharma.com/publications.

Key Points: 
  • “We were excited to present encouraging preclinical data at ISID 2023 highlighting the therapeutic potential of brilaroxazine lipogel, a novel, proprietary lipogel formulation for the topical treatment of psoriasis.
  • We have filed a composition of matter patent for brilaroxazine-lipogel and a separate patent for its use in psoriasis.
  • Brilaroxazine (RP5063) is a modulator of D and 5-HT receptors with multifaceted activity that may affect underlying psoriasis pathology.
  • Preclinical studies in the imiquimod-induced psoriatic mouse model (BALB/c) were used to evaluate the potential of topical liposomal-gel formulation of brilaroxazine for the treatment of psoriasis.

Harpoon Therapeutics Presents Data for New ProTriTAC™ Development Candidates in TROP2- and ITGB6-expressing Solid Tumors at AACR 2023

Retrieved on: 
Monday, April 17, 2023
AACR, TNF, ITGB6, Neutrophil, Basophil, CRS, Therapeutic index, Pharmacokinetics, American Association for Cancer Research, Quality of life, IL-6, Head, Toxicity, Prostate, Neck, Lung, IL-2, Cytokine release syndrome, Patient, IL-8, SAN, Coagulation, Neoplasm, Lymphocyte, Research, Therapy, Tumor microenvironment, Vaccine

“TROP2 and ITGB6 are tumor targets that are overexpressed in numerous solid tumor types and have demonstrated clinical utility when targeted as antibody drug conjugates,” said Luke Walker, M.D., Chief Medical Officer of Harpoon Therapeutics.

Key Points: 
  • “TROP2 and ITGB6 are tumor targets that are overexpressed in numerous solid tumor types and have demonstrated clinical utility when targeted as antibody drug conjugates,” said Luke Walker, M.D., Chief Medical Officer of Harpoon Therapeutics.
  • “However, significant unmet needs remain as both the depth and the durability of response with antibody drug conjugates are typically limited.
  • For more details about the AACR Annual Meeting, please visit:
    The posters will be available on Harpoon’s website following today’s presentations.
  • This spatial control of activation may address on-target tissue damage, hence enabling an expansion of the T cell engager target space.

AIM ImmunoTech Reports Positive Safety, Tolerability and Biological Activity Data for Intranasal Ampligen® (Rintatolimod) in Healthy Subjects

Retrieved on: 
Thursday, December 8, 2022
Smallpox vaccine, Event, RNA, B cell, Immunology, Society, Chronic fatigue syndrome, CFS, Special access program, EAP, NYSE, Influenza and Other Respiratory Viruses, Pancreatic cancer, RANTES, AES, British Society for Research on Ageing, Safety, Physician, Monocyte, AIM, Degenerative disease, Erasmus MC, TNF, Vaccinia, IL-8, Chemokine, Inspectorate, ME/CFS, TLR3, PSLRA, IL-6, Infection, Patient, CXCL10, Immune system, Research, Disease, Interferon, Cancer, Severe acute respiratory syndrome coronavirus 2, COVID-19, CHDR, Granulocyte, Therapy, Vaccine, Pharmaceutical industry, Rintatolimod, MCP-1

OCALA, Fla., Dec. 08, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, today reported that data were recently presented by Lisanne C.A. Smidt - Centre for Human Drug Research (CHDR), Leiden, the Netherlands in a poster titled, “Safety, tolerability and biological activity of repeated intranasal administration of TLR3 agonist Ampligen (Poly I:Poly C12U) in healthy subjects,” at the British Society for Immunology Congress 2022 . The data showed positive safety, tolerability and biological activity of a 13-day dosing regimen conducted in Q2 2021 for intranasal Ampligen® (rintatolimod) in healthy subjects.

Key Points: 
  • Smidt - Centre for Human Drug Research (CHDR), Leiden, the Netherlands in a poster titled, “Safety, tolerability and biological activity of repeated intranasal administration of TLR3 agonist Ampligen (Poly I:Poly C12U) in healthy subjects,” at the British Society for Immunology Congress 2022 .
  • The data showed positive safety, tolerability and biological activity of a 13-day dosing regimen conducted in Q2 2021 for intranasal Ampligen® (rintatolimod) in healthy subjects.
  • Intranasal administration of Ampligen could induce an innate mucosal immune response, thereby inhibiting respiratory viruses at the point of entry.
  • Among other things, for those statements, the Company claims the protection of safe harbor for forward-looking statements contained in the PSLRA.

Neuvivo's NP001 for Treatment of ALS Slows Disease Progression Through Regulation of Microbial Translocation

Retrieved on: 
Thursday, December 1, 2022
MOA, HGF, Doctor of Philosophy, Wound healing, Emeritus, Biomarker, IL-6, Neopterin, Inflammation, Macrophage, Blood, Bacteria, Patient, UCSF, IL-8, McGrath, EGF, Maintenance, Protein, Central nervous system, LPS, LBP, Neurodegeneration, Prognosis, Death, ALS, Plasma, Research, Clinical trial, Neuron, Infection, Microorganism, FDA, HIV disease progression rates, Medical imaging, Vaccine, Pharmaceutical industry, MD, Biomedicine, Medicine

PALO ALTO Calif., Dec. 1, 2022 /PRNewswire/ -- Neuvivo today announced the publication of a peer-reviewed paper titled: "Macrophage Targeted Sodium Chlorite (NP001) Slows Progression of ALS through Regulation of Microbial Translocation". The goal of the biomarker-focused study was to test the relationship between NP001 macrophage-targeted immune regulation and the theory that microbial translocation contributed to ALS progression.

Key Points: 
  • The goal of the biomarker-focused study was to test the relationship between NP001 macrophage-targeted immune regulation and the theory that microbial translocation contributed to ALS progression.
  • "The current study links the regulation of the innate immune system by NP001 with ALS disease modification."
  • McGrath, MD, PhD
    Published in the journal 'Biomedicines', the peer-reviewed study shows a clear relationship between microbial translocation, inflammation, and disease pathogenesis.
  • A total of 9 biomarkers showed notable changes in the blood of patients treated with NP001 as compared to controls, linking a slowing of ALS disease progression with the regulation of microbial translocation.

Protara Therapeutics Announces Trials in Progress Poster Presentation for the ADVANCED-1 Trial in NMIBC at the 23rd Annual Meeting of the Society of Urologic Oncology

Retrieved on: 
Thursday, December 1, 2022
COVID-19, Microcystic lymphatic malformation, United, LM, IL-6, Degenerative disease, Food and Drug Administration, Urology, Granulocyte colony-stimulating factor, TNF, Streptococcus, Food, Safety, LMS, CIS, Therapy, Granulocyte-macrophage colony-stimulating factor, Lymphocyte, Patient, IL-8, Monocyte, Neutrophil, Society, Cytokine, Neoplasm, Date, Annual general meeting, Streptococcus pyogenes, IL-12, Cancer, Cyst, Bladder cancer, FDA, Pharmaceutical industry, Risk management, NMIBC

The ADVANCED-1 study is evaluating TARA-002, an investigational cell-based immunopotentiator, for the treatment of non-muscle invasive bladder cancer (NMIBC).

Key Points: 
  • The ADVANCED-1 study is evaluating TARA-002, an investigational cell-based immunopotentiator, for the treatment of non-muscle invasive bladder cancer (NMIBC).
  • In the initial dose escalation phase of the trial, patients will receive six weekly intravesical doses of TARA-002.
  • Bladder cancer is the 6th most common cancer inthe United States, with NMIBC representing approximately 80% of bladder cancer diagnoses.
  • Protara is committed to identifying and advancing transformative therapies for people with cancer and rare diseases with limited treatment options.

Evelo Biosciences Reports Third Quarter 2022 Financial Results and Business Highlights

Retrieved on: 
Monday, November 14, 2022
Marketing, TH1, RNA-Seq, Inflammation, Chemistry, EV, Seminal vesicles, Research, Chorionic gonadotropin beta, Risk, Inflammatory bowel disease, European Medicines Agency, IL-6, Allergy, TNF, Conference, Patient, IL-8, Arthritis, Cytokine, European Academy of Allergy and Clinical Immunology, CTA, T helper 17 cell, Development, FDA, COVID-19, Growth, Health care, EMA, Physician, Disease, Volunteering, Failure, Clinical trial, Atopic dermatitis, EVS, CMC, Administration, Poster, PASI, Psoriasis Area and Severity Index, Blood, Asthma, MHRA, Confidentiality, Congress, Pharmaceutical industry, Medical device, Dietary supplement, Dermatology, Venereology, Psoriasis

CAMBRIDGE, Mass., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting on the small intestinal axis, SINTAX, today announced its third quarter 2022 financial results and business highlights.

Key Points: 
  • Recruitment for the first three cohorts in the Phase 2 trial of EDP1815 in atopic dermatitis is complete.
  • Recruitment for the fourth cohort is ahead of schedule, with data expected in the second quarter of 2023.
  • In September 2022, Evelo presented a poster at the 2022 European Academy of Dermatology and Venereology (EADV) Congress.
  • In October 2022, Evelo presented two posters at the 2022 Fall Clinical Dermatology Conference.

Ashvattha Therapeutics Announces Publication of Data in Science Translational Medicine from Phase 2a Clinical Trial for OP-101 in Severe COVID-19 Showing Significant Reduction in Inflammatory and Neuroinflammatory Markers and Improved Clinical Outcomes

Retrieved on: 
Monday, July 25, 2022
Death, Inflammation, Multiple organ dysfunction syndrome, Ashvattha, GLOBE, DME, Microglia, Infection, CEO, AMD, IL-6, Lists of diseases, Therapy, GFAP, COVID-19, Safety, NAC, IL-8, Neuro, HDS, Science Translational Medicine, Technology, Patient, HDT, Survival, Neurology, Diabetic retinopathy, Transfusion-related acute lung injury, AFL, Johns Hopkins University, Pharmaceutical industry, Health insurance, Ophthalmology

The paper, titled, Dendrimer nanotherapy for severe COVID-19 attenuates inflammation and neurological injury markers and improves outcomes in a phase 2a clinical trial, was published in the peer-reviewed scientific journal Science Translational Medicine.

Key Points: 
  • The paper, titled, Dendrimer nanotherapy for severe COVID-19 attenuates inflammation and neurological injury markers and improves outcomes in a phase 2a clinical trial, was published in the peer-reviewed scientific journal Science Translational Medicine.
  • Treatment with OP-101 was associated with attenuating neuronal injury markers NfL and GFAP, lasting until day 30 of the study.
  • This paper was published in its entirety in volume 14, issue number 654 of Science Translational Medicine and can be accessed here .
  • Ashvattha Therapeutics is a clinical-stage biotech company developing novel hydroxyl dendrimer therapeutics (HDTs) targeting unmet medical needs in ophthalmology, neurology, inflammatory diseases and neuro-oncology.